Modeling the impact of a long-term horizon and multiple treatment episodes on estimates of the cost-effectiveness of alcohol treatment in the United States

被引:2
|
作者
Barbosa, Carolina [1 ]
Dowd, William N. [1 ]
Karriker-Jaffe, Katherine J. [2 ,3 ]
Zarkin, Gary [1 ]
机构
[1] RTI Int, 3040 East Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA
[2] RTI Int, Berkeley, CA USA
[3] RTI Int, Behav Hlth Res Div, 2150 Shattuck Ave,Suite 800, Berkeley, CA 94704 USA
关键词
alcohol treatment; alcohol use disorder; cost-effectiveness analysis; drinking patterns; simulation modeling; USE DISORDERS; RISK DRINKING; CONSUMPTION; DEPENDENCE; HEALTH; COMBINE; PHARMACOTHERAPY; INTERVENTIONS; MORTALITY; OUTCOMES;
D O I
10.1111/acer.15186
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
BackgroundMost clinical studies of alcohol use disorder (AUD) treatment have short follow-up periods, underestimating the full benefits of alcohol treatment. Furthermore, clinical studies only consider one treatment cycle and do not account for the need for multiple episodes to treat a chronic recurrent condition.MethodsA validated microsimulation model of the long-term drinking patterns of people with AUD in the United States simulated 10,000 individuals resembling those from a large clinical trial. The model was used to assess the impact of (1) 1-year, 5-year, and lifetime horizon on alcohol treatment cost-effectiveness estimates and (2) no, one, two, four, and unlimited additional treatment episodes on alcohol treatment cost-effectiveness estimates. Model outcomes included healthcare costs, crime costs, labor market productivity, life expectancy, quality-adjusted life years (QALYs), alcohol-related hospitalizations, and deaths. Cost-effectiveness analyses were conducted for two perspectives: a healthcare perspective that included costs from hospitalization and AUD treatment, and a broader societal perspective that also included crime costs and productivity.ResultsThe incremental cost per additional QALY gained for alcohol treatment compared with no treatment decreased from $55,590 after 1 year to $78 when healthcare costs and QALYs were tracked over the lifetime, that is, treatment became more cost effective. Treatment was cost saving for any time frame when the impacts on crime and labor productivity were also accounted for in a societal perspective. Access to multiple treatment episodes dominated (i.e., it was more effective and less costly) than no-treatment and one-episode scenarios. From a healthcare perspective, incremental costs per additional QALY for increasing from a maximum of two to four treatment episodes was $499 and from four to unlimited episodes was $5049. The unlimited treatment scenario dominated all others from a societal perspective. Results were robust in sensitivity analyses.ConclusionsA long-term perspective and multiple episodes of alcohol treatment improve cost-effectiveness estimates. When societal impacts are included, alcohol treatment is cost saving. Results support the value of alcohol treatment.
引用
收藏
页码:2121 / 2137
页数:17
相关论文
共 50 条
  • [21] Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States
    Chen, Jing Voon
    Klein, Timothy M.
    Nesheim, Jeffrey
    Mudd, Paul N., Jr.
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1092 - 1100
  • [22] The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States
    Tremblay, Gabriel
    Dolph, Mike
    Roy, Anuja Nidumolu
    Said, Qayyim
    Forsythe, Anna
    CLINICAL THERAPEUTICS, 2020, 42 (05) : 860 - +
  • [23] LONG-TERM COST-EFFECTIVENESS OF LASMIDITAN, UBROGEPANT AND RIMEGEPANT FOR TREATMENT OF ACUTE MIGRAINE
    Touchette, D.
    Atlas, S. J.
    Agboola, F. O.
    Joshi, M.
    Lee, T. A.
    Chapman, R. H.
    Pearson, S. D.
    Rind, D. M.
    VALUE IN HEALTH, 2020, 23 : S261 - S261
  • [24] Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
    O'Day, Ken
    Rajagopalan, Krithika
    Meyer, Kellie
    Pikalov, Andrei
    Loebel, Antony
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2013, 5 : 459 - 470
  • [25] Long-term treatment costs and cost-effectiveness of restoration repair versus replacement
    Kanzow, Philipp
    Krois, Joachim
    Wiegand, Annette
    Schwendicke, Falk
    DENTAL MATERIALS, 2021, 37 (06) : E375 - E381
  • [26] The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension
    van Gestel, Aukje
    Schouten, Jan S. A. G.
    Beckers, Henny J. M.
    Severens, Johan L.
    Hendrikse, Fred
    Webers, Carroll A. B.
    ACTA OPHTHALMOLOGICA, 2014, 92 (06) : 513 - 523
  • [27] The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate
    Palmer, AJ
    Neeser, K
    Weiss, C
    Brandt, A
    Comte, S
    Fox, M
    ALCOHOL AND ALCOHOLISM, 2000, 35 (05): : 478 - 492
  • [28] Cost-Effectiveness of Long-Term Opioid Use in the Treatment of Knee Osteoarthritis in Older Patients with Multiple Comorbidities.
    Katz, Jeffrey N.
    Smith, Savannah
    Collins, Jamie E.
    Jordan, Joanne M.
    Hunter, David J.
    Yelin, Edward H.
    Suter, Lisa
    Paltiel, A. David
    Losina, Elena
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S972 - S973
  • [29] Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States
    Chhatwal, Jagpreet
    Kanwal, Fasiha
    Roberts, Mark S.
    Dunn, Michael A.
    ANNALS OF INTERNAL MEDICINE, 2015, 162 (06) : 397 - U114
  • [30] COST-EFFECTIVENESS OF TREATMENT STRATEGIES FOR SEVERE HEMOPHILIA A PATIENTS IN THE UNITED STATES
    Bolous, N.
    Chen, Y.
    Wang, H.
    Devidas, M.
    Bhakta, N.
    Reiss, U.
    VALUE IN HEALTH, 2022, 25 (07) : S366 - S366